ArticleAfrican health sciences2021
Prevalence and factors associated with non-adherence to multi-drug resistant tuberculosis (MDR-TB) treatment at Mulago National Referral Hospital, Kampala, Uganda.
Article in African health sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Effectiveness of a mobile health application on treatment outcomes among patients with tuberculosis in Shanghai, China: a multicentre randomised controlled trial.BMJ global health · 2025Trial
- Treatment Adherence With an Oral 9-Month Regimen for Rifampicin-Resistant Tuberculosis in South Africa.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Observational
- Weekly pulmonary delivery of β-glucan-chitosan-poly(lactic co-glycolic) acid (β-C-P) nanoparticles with daily standard oral therapy achieves control ofAntimicrobial agents and chemotherapy · 2026Article
- Drug-Resistant Tuberculosis Outcomes in South Kivu Province, Democratic Republic of Congo, During a Humanitarian Crisis (2018-2024).Open forum infectious diseases · 2026Article
- Repeated pulmonary dosing of β-glucan-chitosan-PLGA nanoparticles controlsAntimicrobial agents and chemotherapy · 2026Article
- Success rates of DR-TB patients and associated factors in Tanzania: a six-year cohort study.BMC infectious diseases · 2026Article
- Retreatment TB is a risk factor for multidrug-resistant TB among people with HIV in rural eastern Uganda: A nested case-control study.Journal of clinical tuberculosis and other mycobacterial diseases · 2025Article
- TB-Related Stigma: A Hidden Obstacle to Adherence Monitoring with Video Directly Observed Treatment Among Patients with Tuberculosis in Uganda.Research square · 2025Article
- Integrating narrative and bibliometric approaches to examine factors and impacts of tuberculosis treatment non-compliance.Multidisciplinary respiratory medicine · 2025Article
- Effectiveness, cost, and safety of four regimens recommended by WHO for RR/MDR-TB treatment: a cohort study in Eastern China.Annals of medicine · 2024Article
- Malnutrition and unsuccessful tuberculosis treatment among people with multi-drug resistant tuberculosis in Uganda: A retrospective analysis.Journal of clinical tuberculosis and other mycobacterial diseases · 2024Article
- Article
- First and Second-Line Anti-Tuberculosis Drug-Resistance Patterns in Pulmonary Tuberculosis Patients in Zambia.Antibiotics (Basel, Switzerland) · 2023Article
- A machine learning approach to explore individual risk factors for tuberculosis treatment non-adherence in Mukono district.PLOS global public health · 2023Article
- Article
- Key factors influencing multidrug-resistant tuberculosis in patients under anti-tuberculosis treatment in two centres in Burundi: a mixed effect modelling study.BMC public health · 2021Article
- Determinant factors for loss to follow-up in drug-resistant tuberculosis patients: the importance of psycho-social and economic aspects.BMC pulmonary medicine · 2021Observational
- Non communicable diseases persist despite being overshadowed by Covid-19 globally.African health sciences · 2021Article
- Between Curing and Torturing: Burden of Adverse Reaction in Drug-Resistant Tuberculosis Therapy.Patient preference and adherence · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundIn Uganda, 12% of previously treated TB cases and 1.6% of new cases have MDR-TB and require specialized treatment and care. Adherence is crucial for improving MDR-TB treatment outcomes. There is paucity of information on the extent to which these patients adhere to treatment and what the drivers of non-adherence are.
methodsWe conducted a cohort study using retrospectively collected routine program data for patients treated for MDR-TB between January 2012 - May 2016 at Mulago Hospital. We extracted anonymized data on non-adherence (missing 10% or more of DOT), socio-economic, demographic, and treatment characteristics of the patients. All participants were sensitive to MDR-TB drugs after second line Drug Susceptible Testing (DST) at entry into the study. Factors associated with non-adherence to MDR-TB treatment were determined using generalized linear models for the binomial family with log link and robust standard errors. We considered a p- value less than 0.05 as statistically significant.
resultsThe records of 227 MDR- TB patients met the inclusion criteria, 39.4% of whom were female, 32.6% aged between 25 - 34 years, and 54.6% living with HIV/AIDS. About 11.9% of the patients were non-adherent. The main driver for non-adherence was history of previous DR-TB treatment; previously treated DR-TB patients were 3.46 (Adjusted prevalence ratio: 3.46, 95 % CI: 1.68 - 7.14) times more likely to be non-adherent.
conclusionOne in 10 MDR-TB patients treated at Mulago hospital is non-adherent to treatment. History of previous DRTB treatment was significantly associated with non-adherence in this study. MDR-TB program should strengthen adherence counselling, strengthen DST surveillance, and close monitoring for previously treated DR-TB patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.